Advertisement

Advertisement
John P. Leonard, MD, on NHL: Results From the AUGMENT Trial

John P. Leonard, MD, on NHL: Results From the AUGMENT Trial

Update on Newer Treatments in Non-Hodgkin Lymphomas

Update on Newer Treatments in Non-Hodgkin Lymphomas

AS PART of The ASCO Post’s continued coverage of the 2018 American Society of Hematology Annual Meeting & Exposition, here is an update on several different studies on new therapeutics in non-Hodgkin lymphomas...

Subsequent Primary Neoplasms in Survivors of Adolescent and Young Adult Cancers

In a UK population-based cohort study (Teenage and Young Adult Cancer Survivor Study) reported in The Lancet Oncology, Bright et al found that subsequent primary neoplasms were most common in survivors of adolescent and young adult (AYA) breast,...

DYNAMO: Duvelisib in Refractory Indolent Non-Hodgkin Lymphoma

In the phase II DYNAMO trial reported in the Journal of Clinical Oncology, Flinn et al found a response rate of nearly 50% with duvelisib, an oral dual inhibitor of phosphoinositide 3-kinase (PI3K)-γ and -δ, in indolent non-Hodgkin lymphoma...

2018 Update of WHO-EORTC Classification of Primary Cutaneous Lymphomas

As reported by Willemze and colleagues in Blood, the World Health Organization (WHO) and the European Organisation for Research and Treatment of Cancer (EORTC) have released a 2018 update of their classification of primary cutaneous lymphomas.

As noted...

Advertisement


Advertisement